title: Adalimumab keeps bowel disease in remission aft er up to four years of treatment.
abstract: Long-term treatment with adalimumab can help patients with Crohn's disease maintain remission for up to four years, with no increased risk of adverse effects, according to an analysis of data from two clinical trials.